Monchaux de Oliveira C, Pourtau L, Vancassel S, Pouchieu C, Capuron L, Gaudout D
Nutrients. 2021; 13(3).
PMID: 33799507
PMC: 8001199.
DOI: 10.3390/nu13030904.
Kim C, Byeon S, Shin D
Nutrients. 2020; 12(9).
PMID: 32937844
PMC: 7551178.
DOI: 10.3390/nu12092813.
Kaya B, Yurttas L, Saglik B, Levent S, Ozkay Y, Kaplancikli Z
J Enzyme Inhib Med Chem. 2017; 32(1):193-202.
PMID: 28097890
PMC: 6009961.
DOI: 10.1080/14756366.2016.1247054.
Rudorfer M, Manji H, Potter W
Drug Saf. 1994; 10(1):18-46.
PMID: 8136085
DOI: 10.2165/00002018-199410010-00003.
Jue S, Dawson G, Brogden R
Drugs. 1982; 24(1):1-23.
PMID: 7049659
DOI: 10.2165/00003495-198224010-00001.
Pressor sensitivity to tyramine in patients with headache: relationship to platelet monoamine oxidase and to dietary provocation.
Peatfield R, Littlewood J, Glover V, Sandler M, ROSE F
J Neurol Neurosurg Psychiatry. 1983; 46(9):827-31.
PMID: 6619891
PMC: 1027565.
DOI: 10.1136/jnnp.46.9.827.
A double-blind placebo-controlled study to compare the autonomic effects of fluvoxamine with those of amitriptyline and doxepin in healthy volunteers.
Wilson W, Higano H, Papadatos Y, Kelwala S, Ban T
Br J Clin Pharmacol. 1983; 15 Suppl 3:385S-392S.
PMID: 6407500
PMC: 1427650.
DOI: 10.1111/j.1365-2125.1983.tb02129.x.
Efficacy and side effects of mianserin, a tetracyclic antidepressant.
Wakeling A
Postgrad Med J. 1983; 59(690):229-31.
PMID: 6346303
PMC: 2417496.
DOI: 10.1136/pgmj.59.690.229.
Zimelidine: a review of its pharmacological properties and therapeutic efficacy in depressive illness.
Heel R, Morley P, Brogden R, Carmine A, Speight T, Avery G
Drugs. 1982; 24(3):169-206.
PMID: 6215240
DOI: 10.2165/00003495-198224030-00001.
Hyperventilation syndrome.
Brashear R
Lung. 1983; 161(5):257-73.
PMID: 6138480
DOI: 10.1007/BF02713872.
The functional consequences of inhibition of monoamine oxidase type B: comparison of the pharmacological properties of L-deprenyl and MDL 72145.
Fozard J, Zreika M, Robin M, Palfreyman M
Naunyn Schmiedebergs Arch Pharmacol. 1985; 331(2-3):186-93.
PMID: 3937059
DOI: 10.1007/BF00634237.
A comparison of the cardiovascular effects and subjective tolerability of binedaline and amitriptylene in healthy volunteers.
Joubert P, Starke D, van Reenen O, Venter C
Eur J Clin Pharmacol. 1985; 27(6):667-70.
PMID: 3886394
DOI: 10.1007/BF00547046.
Short-acting novel MAO inhibitors: in vitro evidence for the reversibility of MAO inhibition by moclobemide and Ro 16-6491.
Keller H, Kettler R, Keller G, Da Prada M
Naunyn Schmiedebergs Arch Pharmacol. 1987; 335(1):12-20.
PMID: 3574489
DOI: 10.1007/BF00165029.
Comparative effects of fluoxetine and amitriptyline on cardiac function.
Upward J, Edwards J, Goldie A, Waller D
Br J Clin Pharmacol. 1988; 26(4):399-402.
PMID: 3263876
PMC: 1386560.
DOI: 10.1111/j.1365-2125.1988.tb03397.x.
Fluvoxamine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness.
Benfield P, Ward A
Drugs. 1986; 32(4):313-34.
PMID: 3096686
DOI: 10.2165/00003495-198632040-00002.
Effect of imipramine treatment on changes in heart rate and blood pressure during postural and isometric handgrip tests.
Yeragani V, Meiri P, Balon R, Pohl R, Golec S
Eur J Clin Pharmacol. 1990; 38(2):139-44.
PMID: 2338110
DOI: 10.1007/BF00265972.
Which antidepressant?.
Matthews K, Eagles J
Br J Gen Pract. 1991; 41(344):123-5.
PMID: 2031757
PMC: 1371627.
Paroxetine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depressive illness.
Dechant K, Clissold S
Drugs. 1991; 41(2):225-53.
PMID: 1709852
DOI: 10.2165/00003495-199141020-00007.
